Patients with severe complications or severe infection;
Invasion of central nervous system;
Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;
patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;
patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;
Patients participate in other clinical studies;
Other patients who are not suitable for the study.

NCT02526823_exc_T1
Condition
complications
NCT02526823_exc_T2
Qualifier
severe
NCT02526823_exc_T3
Qualifier
severe
NCT02526823_exc_T4
Condition
infection
NCT02526823_exc_T5
Condition
Invasion
NCT02526823_exc_T6
Qualifier
central nervous system
NCT02526823_exc_T7
Condition
heart disease
NCT02526823_exc_T8
Qualifier
severe
NCT02526823_exc_T9
Condition
ventricular tachycardia
NCT02526823_exc_T10
Condition
VT
NCT02526823_exc_T11
Condition
atrial fibrillation
NCT02526823_exc_T12
Condition
AF
NCT02526823_exc_T13
Condition
heart block
NCT02526823_exc_T14
Condition
myocardial infarction
NCT02526823_exc_T15
Condition
MI
NCT02526823_exc_T16
Condition
congestive heart failure
NCT02526823_exc_T17
Condition
CHF
NCT02526823_exc_T18
Condition
coronary heart disease
NCT02526823_exc_T19
Scope
ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease
NCT02526823_exc_T20
Condition
allergic
NCT02526823_exc_T21
Qualifier
severe
NCT02526823_exc_T22
Condition
allergic
NCT02526823_exc_T23
Condition
intolerant
NCT02526823_exc_T24
Procedure
chemotherapy regimens
NCT02526823_exc_T25
Scope
allergic to or intolerant
NCT02526823_exc_T26
Qualifier
other
NCT02526823_exc_T27
Condition
malignant tumors
NCT02526823_exc_T28
Temporal
past 5 years
NCT02526823_exc_T29
Drug
doxorubicin
NCT02526823_exc_T30
Drug
adriamycin
NCT02526823_exc_T31
Multiplier
more than 300 mg/m2
NCT02526823_exc_T32
Qualifier
total cumulative dose
NCT02526823_exc_T33
Drug
Patients
NCT02526823_exc_T34
Drug
epirubicin
NCT02526823_exc_T35
Qualifier
total cumulative dose
NCT02526823_exc_T36
Multiplier
more than 450 mg/m2